Drug intelligence / Profile preview

PRAK-05221

Development stage: Preclinical
Lead developer: Premas Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PRAK-05221 is a virus-like particle (VLP) vaccine candidate developed by Premas Biotech for the prevention of Respiratory Syncytial Virus (RSV) infection. Utilizing the company's proprietary D-Crypt platform, the vaccine presents RSV antigens in a structural format that mimics the native virus, intended to induce a robust and protective antiviral immune response. As of 2024, the program is in the research and pre-clinical stages of development.

Targets

BCR (Immunoglobulin G B Cell Receptor)RSV G (Respiratory syncytial virus attachment glycoprotein)T-cell receptor recognizing Respiratory Syncytial Virus-derived peptides presented by Major Histocompatibility Complex (RSV-specific TCR)

Beyond the preview

Go deeper on PRAK-05221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRAK-05221.

Explore the full profile